You have read all your free articles, to continue reading subscribe to read the rest of this content.
BioInvent International has restructured a clinical development agreement with Cancer Research UK (CRUK) for its anti-FcγRIIB antibody, BI-1206. In exchange for a one-time payment, the revised deal simplifies and reduces BioInvent’s obligations to CRUK, which provides BioInvent with more flexiAlready a subscriber Login You have read all your free articles,…
Exact Therapeutics announces that its shares have been admitted to trading on Oslo Stock Exchange’s Merkur Market under the ticker EXTX-ME with first day of trading 14 July 2020, following the successful completion of a NOK 155 million private placement. Following a bookbuilding period from 4 -Already a subscriber Login…
SciBase Holding announces that the secured new share issue with preferential rights for existing shareholders has been completed and will provide the company with approximately SEK 75 million before deduction of transaction costs. A total of approximately SEK 39.2 million, corresponding to 46.1 pAlready a subscriber Login You have read…
Danish drugmaker Novo Nordisk expects to double its annual revenue within the next ten years, according to deputy CEO Kåre Schultz. Novo Nordisk has had a tough year so far as the company failed to post double-digit sales growth in the first quarter for the first time in four years. But the rAlready…
